Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
复制标题
DOI：
10.1038/s41591-022-01721-6
复制
发表时间：
2022-05
期刊：
影响因子：
82.9
通讯作者：
Eyre, David W.
中科院分区：
文献类型：
--
作者：
Wei, Jia;Pouwels, Koen B.;Stoesser, Nicole;Matthews, Philippa C.;Diamond, Ian;Studley, Ruth;Rourke, Emma;Cook, Duncan;Bell, John, I;Newton, John N.;Farrar, Jeremy;Howarth, Alison;Marsden, Brian D.;Hoosdally, Sarah;Jones, E. Yvonne;Stuart, David, I;Crook, Derrick W.;Peto, Tim E. A.;Walker, A. Sarah;Eyre, David W.
抗体反应是 2019 年冠状病毒病 (COVID-19) 疫苗接种后免疫的重要组成部分。然而，第二剂疫苗后的抗体轨迹和相关的保护持续时间仍不清楚。在这项研究中，我们调查了英国普通人群接种第二剂针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的 ChAdOx1 或 BNT162b2 疫苗后的抗尖峰 IgG 抗体反应以及保护的相关性。在 222,493 名个体中，我们发现在所有年龄段和使用不同的给药间隔（包括 BNT162b2 的 3 周间隔）时，第二剂两种疫苗的抗尖峰 IgG 显着增强。第二次接种后，BNT162b2 产生的峰值水平高于 ChAdOX1。老年人和男性的 BNT162b2 峰值水平较低，但 ChAdOx1 的峰值水平较低，而不同年龄和性别的 ChAdOX1 或 BNT162b2 的下降幅度相似。既往感染两种疫苗的抗体峰值水平和半衰期均显着增加。抗尖峰 IgG 水平与接种疫苗后免受感染的保护有关，并且在更大程度上与先前感染后的感染保护有关。据估计，在接种两次 ChAdOx1 疫苗后，至少 67% 的感染保护作用可持续持续 2-3 个月，在未曾感染过疫苗的人群中，在接种两次 BNT162b2 疫苗后，可持续 5-8 个月，而在自然感染后未接种疫苗的人群中，则可持续 1-2 年。可能需要第三次加强剂量，优先考虑 ChAdOx1 接受者和临床上更脆弱的人。英国的一项大型研究表明，在先前未感染的个体中，与接种两剂 ChAdOx1 疫苗后相比，接种两剂 BNT162b2 疫苗后，与至少 67% 的 SARS-CoV-2 Delta 变体感染保护相关的病毒特异性抗体水平持续时间更长。
Antibody responses are an important part of immunity after Coronavirus Disease 2019 (COVID-19) vaccination. However, antibody trajectories and the associated duration of protection after a second vaccine dose remain unclear. In this study, we investigated anti-spike IgG antibody responses and correlates of protection after second doses of ChAdOx1 or BNT162b2 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United Kingdom general population. In 222,493 individuals, we found significant boosting of anti-spike IgG by the second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOX1. Older individuals and males had lower peak levels with BNT162b2 but not ChAdOx1, whereas declines were similar across ages and sexes with ChAdOX1 or BNT162b2. Prior infection significantly increased antibody peak level and half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2–3 months after two ChAdOx1 doses, for 5–8 months after two BNT162b2 doses in those without prior infection and for 1–2 years for those unvaccinated after natural infection. A third booster dose might be needed, prioritized to ChAdOx1 recipients and those more clinically vulnerable. A large study in the United Kingdom shows that virus-specific antibody levels associated with at least 67% protection against SARS-CoV-2 Delta variant infection last longer after two doses of BNT162b2 vaccine than after two doses of ChAdOx1 vaccine in previously uninfected individuals.
登录
查看更多内容
影响因子：
7.8
作者：
Amodio E;Capra G;Casuccio A;Grazia S;Genovese D;Pizzo S;Calamusa G;Ferraro D;Giammanco GM;Vitale F;Bonura F
通讯作者：
Bonura F
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.1016/j.ijid.2021.07.070
发表时间：
2021-10
期刊：
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
影响因子：
--
作者：
Claro F;Silva D;Rodriguez M;Rangel HR;de Waard JH
通讯作者：
de Waard JH
影响因子：
64.5
作者：
Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
4.6
作者：
Maeda K;Amano M;Uemura Y;Tsuchiya K;Matsushima T;Noda K;Shimizu Y;Fujiwara A;Takamatsu Y;Ichikawa Y;Nishimura H;Kinoshita M;Matsumoto S;Gatanaga H;Yoshimura K;Oka SI;Mikami A;Sugiura W;Sato T;Yoshida T;Shimada S;Mitsuya H
通讯作者：
Mitsuya H